Terrie Curran

Track

Insider profile

Currently holds positions in Myovant Sciences Ltd and Celgene Corp

Performance

Overall performance
3.1
Performance over holding periods
4.2
30 days 90 days 120 days
Average return -5% 8.2% 15.1%
Success rate 12% 68% 82%
Transactions
9 22% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 15%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Independent Director Myovant Sciences Ltd Nov. 15, 2016 -
President, Global Inflammation & Immunology Franchise Celgene Corp April 1, 2017 -
Terrie Curran's trades of Arcutis Biotherapeutics, Inc.'s stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Planned sale
Price
25.58
Quantity 4,850 -100.0%
Value US$124,063
US Celgene Corp (CELG)
Transaction date
Sale
Price
98.31
Quantity 6,838 -76.0%
Value US$672,244
US Celgene Corp (CELG)
Transaction date
Sale
Price
98.20
Quantity 4,500 -33.4%
Value US$441,900
Transaction date
Purchase
Price
0.10
Quantity 170,501
Value £17,050
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-28 2026-08-27
S Sale
10,935 +7.5%
484.23
US$3,619,261 		10,935 +7.5% 484.23 US$3,619,261
2026-08-28 2026-08-27
S Sale
31,386 -4.2%
341.50
US$2,638,111 		31,386 -4.2% 341.50 US$2,638,111
2026-08-27 2026-08-27
PrS Proposed sale
42,295
433.47
US$4,066,093 		42,295 433.47 US$4,066,093
2026-08-24 2026-08-20
S Sale
1,072 -4.4%
26.04
US$27,912 		1,072 -4.4% 26.04 US$27,912
2026-08-20 2026-08-20
PrS Proposed sale
1,072
26.04
US$27,912 		1,072 26.04 US$27,912
2025-01-23 2025-01-21
PlS Planned sale
19,109 -5.0%
6.59
US$125,884 		19,109 -5.0% 6.59 US$125,884
2024-11-13 2024-11-11
S Sale
8,687 -46.1%
10.85
US$94,238 		8,687 -46.1% 10.85 US$94,238
2024-11-12 2024-11-11
PrS Proposed sale
8,687
10.85
US$94,238 		8,687 10.85 US$94,238
2024-07-17 2024-07-15
PlS Planned sale
33,848 -8.2%
11.72
US$396,699 		33,848 -8.2% 11.72 US$396,699
2024-03-26 2024-03-22
PlS Planned sale
16,851 -3.9%
9.11
US$153,513 		16,851 -3.9% 9.11 US$153,513
2023-04-07 2023-04-06
B Purchase
12,919 +7.4%
7.82
US$101,025 		12,919 +7.4% 7.82 US$101,025
2023-03-03 2023-03-01
PlS Planned sale
1,436 -0.8%
8.54
US$12,265 		1,436 -0.8% 8.54 US$12,265
2023-01-20 2023-01-20
S Sale
5,821 -3.2%
8.20
US$47,729 		5,821 -3.2% 8.20 US$47,729
2022-11-23 2022-11-21
S Sale
1,526 -1.8%
9.60
US$14,650 		1,526 -1.8% 9.60 US$14,650
2022-05-16 2022-05-13
B Purchase
20,500 +46.5%
7.41
US$151,835 		20,500 +46.5% 7.41 US$151,835
2021-09-13 2021-09-09
PlS Planned sale
4,850 -100.0%
25.58
US$124,063 		4,850 -100.0% 25.58 US$124,063
2021-03-23 2021-03-22
S Sale
1,140 -100.0%
44.08
US$50,256 		1,140 -100.0% 44.08 US$50,256
2021-03-23 2021-03-22
PlS Planned sale
10,373 -90.1%
43.24
US$448,495 		10,373 -90.1% 43.24 US$448,495
2019-09-19 2019-09-18
US Celgene Corp (CELG)
S Sale
6,838 -76.0%
98.31
US$672,244 		6,838 -76.0% 98.31 US$672,244
2019-09-19 2019-09-18
US Celgene Corp (CELG)
S Sale
4,500 -33.4%
98.20
US$441,900 		4,500 -33.4% 98.20 US$441,900
2018-08-30 2018-08-30
B Purchase
170,501
0.10
£17,050 		170,501 0.10 £17,050